Taxane-induced peripheral neuropathy more common in patients with diabetes longer than 5 years

the ONA take:

Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for developing severe peripheral sensory neuropathy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.

For the study, researchers in Turkey sought to determine whether the presence of diabetes mellitus impacts the incidence and severity of peripheral sensory neuropathy in patients undergoing taxane therapy for cancer. Researchers retrospectively analyzed data from 374 patients receiving taxane therapy at a single institution. Of those, 21.6% had diabetes.

Results showed that the incidence of grade 1 peripheral neuropathy in patients receiving taxane-based therapy was 33.4% in non-diabetics and 25.9% in those with diabetes; however, the incidence of grade 2 or higher peripheral neuropathy was 15% and 34.6%, respectively.

Researchers found that the overall incidence of peripheral neuropathy was 48.8% in non-diabetic patients, 52.8% in patients with diabetes less than 5 years, and 75% in patients with diabetes for longer than 5 years.

Taxane-induced peripheral neuropathy more common in patients with diabetes longer than 5 years
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for neuropathy.
The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence and severity of peripheral sensory neuropathy (PSN) in patients using taxane therapy. A retrospective single-center analysis was conducted: Patients with PSN at baseline were excluded.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs